$PHIO News

Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate

Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event

Phio Pharma Enters Into At The Market Offering Agreement With H.C. Wainwright; Phio To Offer Up To $6.36M Of Shares Under Sales Agreement

Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply

Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Phio Pharma Q4 EPS $(0.15) Beats $(0.41) Estimate

Phio Pharma Q4 EPS $(0.15) Beats $(0.41) Estimate

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

Phio Pharma Promotes Lisa Carson To CFO

Here are the top movers in Wednesday's session.

Top movers in Wednesday's session

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee has concluded its review of PH-762 Phase 1b trial, reporting no serious adverse events or dose-limiting toxicities.

HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target